Published on
April 24, 2023
- 20:15 GMT
Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia
-Virios’ IMC-1 Phase 3 Proposed Program is Considered Acceptable based on Initial FDA Feedback Pending Review of the Final Chronic Toxicology Program Results- -Final Toxicology Results to be Submitted to FDA in May 2023- -Company will Provide Material …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
